TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04783376

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: : Insulin, lispro and regular insulin
Description: * A: the participant will have a mealtime bolus dose of fast-acting insulin 10 minutes before the meal representing 100% of the dose calculated according to the carbohydrate content of the meal and the individual insulin to carbohydrate ratio~* B: the bolus insulin dose for the meal will be calculated according to the carbohydrate content of the meal and the individual insulin to carbohydrate ratio and additional 30% of the calculated dose will added to cover the fat and protein content of the meal. This total dose will be divided into 2 portions. A premeal portion (60%) will be given 10 minutes before the meal and (40%) will be given 30 minutes after the premeal dose. Both doses will be given as fast-acting insulin.~* C: the same as intervention B but the 40% of the total dose will be given as regular insulin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: : Insulin, lispro and regular insulin
Description: * A: the participant will have a mealtime bolus dose of fast-acting insulin 10 minutes before the meal representing 100% of the dose calculated according to the carbohydrate content of the meal and the individual insulin to carbohydrate ratio~* B: the bolus insulin dose for the meal will be calculated according to the carbohydrate content of the meal and the individual insulin to carbohydrate ratio and additional 30% of the calculated dose will added to cover the fat and protein content of the meal. This total dose will be divided into 2 portions. A premeal portion (60%) will be given 10 minutes before the meal and (40%) will be given 30 minutes after the premeal dose. Both doses will be given as fast-acting insulin.~* C: the same as intervention B but the 40% of the total dose will be given as regular insulin.
Study: NCT06628310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: IV Infusion; IV Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: IV Infusion; IV Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: IV Infusion; IV Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: IV Infusion; IV Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: IV Infusion; IV Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: IV Infusion; IV Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: IV Infusion; IV Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: IV Infusion; IV Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV Infusion
Study: NCT04416451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Induction:Rituximab will be administered per institutional guidelines once per week for 4 weeks at a dose of 375 mg/m\^2. Maintenance: In addition, patients will receive rituximab 375 mg/m2 starting on day 1 of the maintenance phase and repeated once every 3 months for 12 months (for a total of 4 infusions). On days when venetoclax and rituximab will both be administered, patients will take venetoclax prior to administration of rituximab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Induction: Starting one week after the last induction dose of rituximab (approximately week 5), venetoclax will be administered orally at a flat dose of 100 mg daily and escalating each week to a target dose of 800 mg daily on the following schedule:~* Week 1: 100 mg~* Week 2: 200 mg~* Week 3: 400 mg~* Week 4: 800 mg Maintenance: Following the 4-week induction phase ramp-up of venetoclax, patients will begin their target dose of 800 mg venetoclax daily and continue this dose during the 24- month maintenance treatment phase. On days when venetoclax and rituximab will both be administered, patients will take venetoclax prior to administration of rituximab.
Study: NCT06627322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual-combination therapy
Description: Group 1: Metformin/DPP-4i-based or Metformin/SGLT2i-based dual-combination therapy. Any oral antiglycemic drugs on the market.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple-combination therapy
Description: Group 2: Metformin/SGLT2i/DPP-4i-based triple-cobmination therapy, or Group 3: Metformin/SGLT2i/Thiazolidinedione-based triple-cobmination therapy Any oral antiglycemic drugs on the market.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G7, Pasta
Description: Real-time continous glucose monitoring system (CGMS) Device (sensor): Dexcom G7 Device (software): Kakaohealthcare Pasta Barozen Fit is also available.
Study: NCT06627036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermatoscope
Description: For participants in the dermoscopy group, the marking will also be done preoperatively with a marker pen, but the lesion borders will be determined using a dermatoscope. A peripheral margin based on BAD guidelines will be marked similarly.
Study: NCT06627088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4100511 (DC-853)
Description: Administered oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LY4100511 (DC-853) Administered oral dose
Description: Administered oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4100511 (DC-853)
Description: Administered oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LY4100511 (DC-853)
Description: Administered IV infusion
Study: NCT06622538

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orotracheal intubation
Description: Patients who meet the inclusion criteria and sign the informed consent form will be intubated with the ORION or King Vision video laryngoscope according to randomisation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orotracheal intubation
Description: Patients who meet the inclusion criteria and sign the informed consent form will be intubated with the ORION or King Vision video laryngoscope according to randomisation.
Study: NCT06692907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B7A (ETEC challenge strain)
Description: A pathogenic strain of ETEC that can cause illness ranging from mild watery diarrhea to severe symptoms. The primary complication associated with an infection from this strain is dehydration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: B7A (ETEC challenge strain)
Description: A pathogenic strain of ETEC that can cause illness ranging from mild watery diarrhea to severe symptoms. The primary complication associated with an infection from this strain is dehydration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B7A (ETEC challenge strain)
Description: A pathogenic strain of ETEC that can cause illness ranging from mild watery diarrhea to severe symptoms. The primary complication associated with an infection from this strain is dehydration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: B7A (ETEC challenge strain)
Description: A pathogenic strain of ETEC that can cause illness ranging from mild watery diarrhea to severe symptoms. The primary complication associated with an infection from this strain is dehydration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CssBA
Description: A CS6 based vaccine against ETEC (Enterotoxigenic Escherichia coli) in preventing moderate-severe diarrhea obtained via purification from a host E. coli expression strain, BL21(DE3), harboring a pET24a (+) plasmid containing the CssBA gene expressing the his-tagged CssBA protein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CssBA
Description: A CS6 based vaccine against ETEC (Enterotoxigenic Escherichia coli) in preventing moderate-severe diarrhea obtained via purification from a host E. coli expression strain, BL21(DE3), harboring a pET24a (+) plasmid containing the CssBA gene expressing the his-tagged CssBA protein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dmLT
Description: An E. coli double mutant heat labile toxin. This genetically attenuated strain is expressed from a plasmid (pLC403) in the E. coli expression strain JM83.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dmLT
Description: An E. coli double mutant heat labile toxin. This genetically attenuated strain is expressed from a plasmid (pLC403) in the E. coli expression strain JM83.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06693726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II Infusion
Description: Angiotensin II continuous infusion
Study: NCT06693518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Ibuzatrelvir 600 mg + Dabigatran Etexilate 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Dabigatran Etexilate 150 mg
Study: NCT06693570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intact Fish Skin Graft (IFSG) + Standard of Care
Description: Participants will receive weekly applications of MariGen and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
Study: NCT06533657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trichomylin® capsule (5 mg delta-9-tetrahydrocannabinol: 5 mg cannabidiol: 5 mg cannabichromene)
Description: Cancer patients meeting eligibility criteria will receive Trichomylin® and self-titrate to effective dose.
Study: NCT06679140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuzatrelvir
Description: ibuzatrelvir tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets
Study: NCT06695013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zanubrutinib
Description: zanubrutinib 160 mg BID orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zanubrutinib
Description: zanubrutinib 160 mg BID orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T
Description: CAR-T Cell therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAR-T
Description: CAR-T Cell therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Bridging radiotherapy
Description: For patients in the experimental group, the decision regarding radiotherapy will depend on whether the specific lesions are suitable.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg IV Q3-4W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: 200mg IV Q3-4W
Study: NCT06691854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The group that applied the Intrapartum Care Model
Description: Pregnant women who apply to the hospital for delivery, have cervical dilatation of 5 cm and above, agree to participate in the study and are assigned to the intervention group;~A Personal Information form will be applied at the first clinic admission. All primiparous pregnant women assigned to the intervention group will be applied the intrapartum care model by the research midwife during the labor process and after birth in line with the WHO positive birth recommendations.~The labor process of the pregnant woman will be recorded on the birth experience follow-up form.~After birth, the Respectful maternity care scale, Birth experience scale, Traumatic birth perception scale will be applied.
Study: NCT06745921

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HydroVax-001B WNV
Description: A vaccine to West Nile Virus (WNV) that is prepared by propagating naturally attenuated Kunjin strain of WNV on well characterized low-passage Vero cells. The vaccine contains 10 mcg of inactivated purified whole virion WNV formulated in a volume of 0.5 mL/dose with 0.10% aluminum hydroxide, 10% D-sorbitol, 0.001% Polysorbate 80 (Tween80) in 10 mM phosphate-buffer with 350 mM NaCl.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HydroVax-001B WNV
Description: A vaccine to West Nile Virus (WNV) that is prepared by propagating naturally attenuated Kunjin strain of WNV on well characterized low-passage Vero cells. The vaccine contains 10 mcg of inactivated purified whole virion WNV formulated in a volume of 0.5 mL/dose with 0.10% aluminum hydroxide, 10% D-sorbitol, 0.001% Polysorbate 80 (Tween80) in 10 mM phosphate-buffer with 350 mM NaCl.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Chloride, 0.9%
Description: 0.9% Sodium Chloride Injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Chloride, 0.9%
Description: 0.9% Sodium Chloride Injection
Study: NCT06772649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression sleeve
Description: The Bauerfeind compression sleeve is a fabric sleeve designed to support the ankle during movement. It's made of a compressive knit material that increases sensorimotor feedback, enhances blood circulation, and stimulates metabolism. The design helps reduce ligament strain, activates the foot's stabilizing muscles more quickly, and improves joint coordination.
Study: NCT05735249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARN-75039 oral capsules
Description: SAD: Up to 5 single escalating doses MAD: Up to 3 escalating doses Food-effect: Selected single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given at frequency and amounts matching ARN- 75039 dosing regimen
Study: NCT05551104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Nifedipine
Description: Administration of oral nifedipine to control postpartum hypertension.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Labetalol
Description: Administration of oral labetalol to control postpartum hypertension.
Study: NCT06517771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online aerobic exercise
Description: Before starting the online aerobic exercises, for general warm-up, two minutes of walking, one minute of marching, and ten repetitions of bilateral reciprocal shoulder flexion-extension, shoulder horizontal abduction-adduction, and unilateral shoulder flexion and circling exercises were performed. For the upper extremity, full elbow extension with shoulder retraction in full shoulder flexion (Exercise V), elbows 90 degrees flexion with shoulder retraction in 90 degrees abduction (Exercise U), and full elbow flexion with shoulder extension of about 30 degrees (Exercise W) were performed. Standing hip abduction-extension, elevation on tiptoe, standing-sitting from a chair with hands on shoulders, squatting, tandem walking, and standing on one leg exercises were performed in the lower extremities. Gastrocnemius, hamstring, and shoulder posterior and inferior capsule stretching exercises were conducted as cooling exercises.
Study: NCT06581965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short duration prophylaxis
Description: Only during hospitalization: any type of LMWH or DOAC in a prophylactic dose as approved by the Dutch guideline Antitrombotisch beleid. First dose of LMWH within 6-24h following surgery. First dose of apixaban within 12-24h following surgery. First dose of rivaroxaban 6-10h following surgery. First dose of dabigatran within 1-4h following surgery. The applied type of anticoagulant is according to the local standard use (same type as used for control group).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Higher intensity and longer duration prophylaxis
Description: The use of any thrombocyte aggregation inhibitors should be discontinued 5 days prior to surgery. Day 0-2: any type of LMWH or DOAC in a prophylactic dose as approved by the Dutch guidelines. First dose of LMWH within 6-24h following surgery. First dose of apixaban within 12-24h following surgery. First dose of rivaroxaban 6-10h following surgery. First dose of dabigatran within 1-4h following surgery. The applied type of anticoagulant is according to the local standard use.~Day 3: Apixaban 5mg b.i.d., continued until 6 weeks after surgery, conditional on the fact that no active bleeding of the surgical wound can be observed. In case of active bleeding, the prophylactic dose of thrombosis prophylaxis is continued. Thereafter, in case no active bleeding has been observed for 24 hours, the 5mg b.i.d. apixaban treatment will be started.~The 5mg b.i.d. apixaban dose will be adjusted to 2.5mg b.i.d. in case of an impaired kidney function (defined as eGFR 10-30ml/min).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: 4 weeks: any type of LMWH or DOAC in a prophylactic dose as approved by the Dutch guidelines. First dose of LMWH within 6-24h following surgery. First dose of apixaban within 12-24h following surgery. First dose of rivaroxaban 6-10h following surgery. First dose of dabigatran within 1-4h following surgery. The applied type of anticoagulant is according to the local standard use.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: 4 weeks: any type of LMWH or DOAC in a prophylactic dose as approved by the Dutch guidelines. First dose of LMWH within 6-24h following surgery. First dose of apixaban within 12-24h following surgery. First dose of rivaroxaban 6-10h following surgery. First dose of dabigatran within 1-4h following surgery. The applied type of anticoagulant is according to the local standard use.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: 4 weeks: any type of LMWH or DOAC in a prophylactic dose as approved by the Dutch guidelines. First dose of LMWH within 6-24h following surgery. First dose of apixaban within 12-24h following surgery. First dose of rivaroxaban 6-10h following surgery. First dose of dabigatran within 1-4h following surgery. The applied type of anticoagulant is according to the local standard use.
Study: NCT06548607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD06-04 CART Cell Injection
Description: CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
Study: NCT05284240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auryon Laser System
Description: The Auryon BTK Study is a prospective, single arm multicenter study evaluating the safety and procedural effectiveness of the Auryon laser in treating infrapopliteal disease in patients with critical limb ischemia and claudication.~The primary exposure of interest for this study is the use of the AURYON system for atherectomy.
Study: NCT05056493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caremap app
Description: The Caremap app is intended for organizing and tracking patient-reported health insights over time and sharing those trends and patient-centered goals with their providers, not for urgent/emergent clinical communication. Information shared with providers through the app will be used for clinical care at the discretion of their provider. Use of the app to share information and health insights will not replace usual, existing channels for patient-provider communication (e.g., MyChart, phone calls, email, pager, etc.).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caremap app
Description: The Caremap app is intended for organizing and tracking patient-reported health insights over time and sharing those trends and patient-centered goals with their providers, not for urgent/emergent clinical communication. Information shared with providers through the app will be used for clinical care at the discretion of their provider. Use of the app to share information and health insights will not replace usual, existing channels for patient-provider communication (e.g., MyChart, phone calls, email, pager, etc.).
Study: NCT05317390

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DystoniaNet-based diagnosis of isolated dystonia
Description: DystoniaNet will be used for the diagnosis of dystonia and its differential diagnosis from other neurological and non-neurological disorders mimicking symptoms of dystonia
Study: NCT04505371

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Intervention for Smokers with HIV
Description: WISH is delivered remotely by mobile phone (voice and text message). WISH addresses both smoking and a number of other personally relevant health behaviors (such as treatment engagement, medication adherence, stress and mood management, social support, alcohol use, etc.), making it relevant and engaging to all, not just those ready to stop smoking. For those not yet ready to quit, WISH is designed to build and strengthen motivation and self-confidence for quitting, while smokers also work on other personal health goals.~Once ready to quit smoking, participants receive evidence-based cognitive-behavioral counseling and encouragement to access nicotine replacement therapy (NRT) or other appropriate pharmacotherapy through usual care VA procedures. Medications will not be prescribed or dispensed by the study.
Study: NCT04163536

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: In the experimental group, methylprednisolone will be administered intravenously for 5 days at a dose of 1 mg/kg/day. Methylprednisolone will be provided for reconstitution and dilution in 50 ml of NaCl 0.9% solution and administered over 15 minutes, once a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: in the control group, placebo will be administered intravenously for 5 days. Placebo will be identical (color and aspect) to experimental substance, will be provide as a 50 mL of NaCl 0.9% solution and administered intravenously over 15 minutes, once a day.